Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the “Mirror Effect” of Schizophrenia
Bibliographic Data
| ID | 15518281 |
|---|---|
| Authors | Joëlle Desfossés (Université de Montréal, corresponding author), Emmanuel Stip (0000-0003-2859-2100, Université de Montréal), Lahcen Aït Bentaleb (Université de Montréal), Olivier Lipp (Université de Montréal), Jean‐Pierre Chiasson, Jean-Pierre Chiasson, Alexandra Fürtös (Université de Montréal), Karine Venne (Université de Montréal), Édouard Kouassi (0000-0002-3626-4863, Université de Montréal), Stéphane Potvin (0000-0003-1624-378X, Université de Montréal) |
| Year | 2012 |
| Volume | 3 |
| Pages | 85-85 |
| Publication date | 2012-01-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2012.00085 |
| PMID | 23055987 |
| PMCID | PMC3457074 |
| OpenAlex | W2117513290 |
| Language | EN |
| Citations received | 3 |
| References cited | 7 |
Schizophrenia is a complex psychiatric disorder strongly associated with substance use disorders. Theoretically, schizophrenia and SUD may share endocannabinoid alterations in the brain reward system. The main endocannabinoids, anandamide, and 2-arachidonoylglycerol, are lipids which bind cannabinoid receptors. Oleoylethanolamide (OEA), a fatty-acid ethanolamide, binds peroxisome proliferator-activated receptors. The endocannabinoid system has been shown to be impaired in schizophrenia, and recently, our group has shown that schizophrenia patients with SUD have elevated peripheral levels of anandamide and OEA that do not normalize after 3-month treatment with quetiapine. Objective For comparative purposes, we aimed to measure endocannabinoids in non-psychosis substance abusers and non-abusing schizophrenia patients. Methods Using liquid chromatography and mass spectrometry, we measured plasma levels of anandamide and OEA in non-psychosis SUD patients, non-abusing schizophrenia patients, and healthy controls. In an open-label manner, all patients received 12-week treatment with quetiapine. Results Anandamide and OEA were reduced in substance abusers without schizophrenia, relative to healthy controls (p < 0.05). Both endocannabinoids were unchanged in non-abusing schizophrenia patients. After quetiapine, anandamide, and OEA levels remained significantly reduced the SUD group (p < 0.05). Discussion Taken together with results of our previous study performed in dual-diagnosis patients, our results suggest that peripheral anandamide and OEA levels are impaired in patients with SUD in opposite ways according to the presence or absence of schizophrenia. Endocannabinoid alterations did not change with treatment, suggesting that they are trait markers. Further studies are necessary to understand the role of endocannabinoids in substance abusers with and without schizophrenia and to examine therapeutic implications
Anandamide · Cannabinoid · Cannabinoid receptor · Endocannabinoid system · Psychiatry · Psychosis · Quetiapine · Receptor · Schizophrenia (object-oriented programming · Cannabis and Cannabinoid Research · Medicine · Neuroscience and Neuropharmacology Research · Neurotransmitter Receptor Influence on Behavior · Psychology · Endocrinology · Internal Medicine
L’impact de la consommation du cannabis sur les symptômes psychiatriques
Peripheral Endogenous Cannabinoid Levels Are Increased in Schizophrenia Patients Evaluated in a Psychiatric Emergency Setting
Sex Differences in Psychiatric Comorbidity and Plasma Biomarkers for Cocaine Addiction in Abstinent Cocaine-Addicted Subjects in Outpatient Settings
| Unique citing works | 3 |
|---|---|
| Citations per year | 0,27 |
| Citation span | 2015 - 2024 (10) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 3 |